Published in Gene Ther on March 04, 2010
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol (2013) 1.64
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant (2015) 0.89
Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. Clin Dev Immunol (2011) 0.87
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol (2012) 0.84
Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol (2014) 0.83
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica (2016) 0.82
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? Immunotherapy (2015) 0.80
Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant (2012) 0.80
Developing strategies in the immunotherapy of leukemias. Cancer Control (2013) 0.79
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther (2016) 0.78
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells (2015) 0.78
Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother (2013) 0.77
New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci (2016) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood (2017) 0.76
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther (2016) 0.76
Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Harnessing the immune response to target tumors. F1000Res (2017) 0.75
No hiding place: on the discomforts of researching the contemporary policy process. J Soc Policy (1990) 8.97
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
Computer-assisted follow-up register for the north-east of Scotland. Br Med J (1970) 3.92
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A (1996) 3.53
Screening for asymptomatic urinary-tract infection in schoolgirls. A two-centre feasibility study. Lancet (1973) 3.10
It's about more than money: financial incentives and internal motivation. Qual Saf Health Care (2005) 3.09
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci (2002) 2.43
Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene (1997) 2.35
Amitriptyline and cardiac disease. Risk of sudden death identified by monitoring system. Lancet (1970) 2.31
A computer assisted follow-up register. Methods Inf Med (1969) 2.29
Health needs assessment. Whose priorities? Listening to users and the public. BMJ (1998) 2.19
Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J Infect Dis (2001) 2.11
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. J Biol Chem (1996) 2.07
NKT cells are phenotypically and functionally diverse. Eur J Immunol (1999) 1.97
CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol (2000) 1.94
Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol (2001) 1.92
Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med (2000) 1.89
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem (1997) 1.88
Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol (2007) 1.80
Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today (1995) 1.76
A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem (1996) 1.75
Role of ceramide in cellular senescence. J Biol Chem (1995) 1.74
Antitussive activity of iodo-resiniferatoxin in guinea pigs. Thorax (2004) 1.73
Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med (2001) 1.70
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant (2005) 1.64
A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia (1981) 1.63
Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci (2001) 1.62
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med (1989) 1.60
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol (1998) 1.59
Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci (2000) 1.58
Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. Soc Sci Med (2001) 1.58
Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol (1998) 1.56
Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. Proc Natl Acad Sci U S A (1992) 1.55
Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med (1997) 1.54
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
The ERGB/Fli-1 gene: isolation and characterization of a new member of the family of human ETS transcription factors. Cell Growth Differ (1992) 1.49
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res (2001) 1.47
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci (2005) 1.46
Evacuation decisions in a chemical air pollution incident: cross sectional survey. BMJ (2005) 1.45
CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol (2007) 1.45
Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med (1999) 1.45
Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis (1991) 1.45
A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ (2003) 1.44
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J (2008) 1.43
The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem (2001) 1.43
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol (2009) 1.42
Positron emission tomography scanning in the assessment of patients with lymphoma. Intern Med J (2004) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol (1993) 1.40
Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer. Med J Aust (1998) 1.40
Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol (2001) 1.40
Investigation of association between alpha-1 proteinase inhibitor haplotype and endometritis in the thoroughbred mare. Equine Vet J (1994) 1.39
Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. Mol Cell Biol (1999) 1.39
Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J Biol Chem (1998) 1.36
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1997) 1.36
Re-thinking accountability: trust versus confidence in medical practice. Qual Saf Health Care (2004) 1.33
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Rules and guidelines in clinical practice: a qualitative study in operating theatres of doctors' and nurses' views. Qual Saf Health Care (2005) 1.29
Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol (2001) 1.25
Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol (1997) 1.25
Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo. J Exp Med (1990) 1.24
An acceptability study of female-controlled methods of protection against HIV and STDs in south-western Uganda. Int J STD AIDS (2000) 1.24
A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J Biol Chem (1997) 1.23
Processing of the Nedd2 precursor by ICE-like proteases and granzyme B. Genes Cells (1996) 1.23
Cell recognition in plants: Determinants of the stigma surface and their pollen interactions. Proc Natl Acad Sci U S A (1976) 1.23
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia (2013) 1.20
Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol (1999) 1.20
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol (2001) 1.19
Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer (1988) 1.19
Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine. J Hyg (Lond) (1983) 1.19
The human cytotoxic T cell granule serine protease granzyme H has chymotrypsin-like (chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes. J Biol Chem (1999) 1.18
Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology (1985) 1.18
Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem (1996) 1.17
Structure and assembly of the capsid of bacteriophage P22. Philos Trans R Soc Lond B Biol Sci (1976) 1.16
Nuclear transport of granzyme B (fragmentin-2). Dependence of perforin in vivo and cytosolic factors in vitro. J Biol Chem (1996) 1.16
Multiple cooperative interactions constrain BPV-1 E2 dependent activation of transcription. Nucleic Acids Res (1989) 1.15
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia (2010) 1.15
Immunopurification of functional Asp-ase (natural killer cell granzyme B) using a monoclonal antibody. Biochem Biophys Res Commun (1993) 1.14
Glial development in the Drosophila CNS requires concomitant activation of glial and repression of neuronal differentiation genes. Development (1997) 1.14